Inclusion Criteria

DISEASE CHARACTERISTICS:

- Cytologically or pathologically verified cancer that is of advanced stage and for
which there is no effective therapy

- No lymphoma

- Measurable or nonmeasurable disease

- Previously irradiated (whole brain or gamma knife) brain metastases allowed provided
there is no requirement for corticosteroids or anticonvulsants

PATIENT CHARACTERISTICS:

- Zubrod performance status 0-2

- ANC ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Hemoglobin ≥ 9 g/dL (without transfusions)

- AST and ALT ≤ 2.5 times upper limit of normal (ULN) (≤ 5 times ULN if liver
metastases present)

- Bilirubin normal

- Serum creatinine ≤ 1.5 times ULN OR measured creatinine clearance OR calculated
creatinine clearance ≥ 60 mL/min

- QTC interval < 480 msec on baseline ECG OR average QTC < 480 msec on baseline plus 2
additional screening ECG's

- Fasting cholesterol < 350 mg/dL

- Fasting triglycerides < 400 mg/dL

- No uncontrolled hypertension, arterial thrombotic event, or bleeding on therapeutic
anticoagulation with warfarin or heparin (including low molecular weight heparin)
within the past 6 months

- Able to swallow enteral medications

- No feeding tubes

- No intractable nausea or vomiting

- No gastrointestinal (GI) tract disease resulting in an inability to take oral
medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical
procedures affecting absorption, or uncontrolled inflammatory GI disease (e.g.,
Crohn, ulcerative colitis)

- No history of allergic reactions attributed to compounds of similar chemical or
biologic composition to rapamycin analogs (e.g., sirolimus and everolimus)

- No known HIV positivity

- No uncontrolled intercurrent illness including, but not limited to, the following:

- Ongoing or serious active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Serious cardiac arrhythmia

- History of myocardial infarction

- Cerebrovascular accident within 3 months of study entry

- Uncontrolled diarrhea

- Psychiatric illness or social situation that would limit compliance with study
requirements

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception, including barrier methods

- Willing to undergo pharmacokinetic (PK) sampling and blood submission for PK and
translational medicine studies

PRIOR CONCURRENT THERAPY:

- Recovered from all prior therapy

- No prior pazopanib hydrochloride or temsirolimus

- More than 28 days since prior major surgery, chemotherapy, biologic therapy, or
immunotherapy

- More than 28 days since prior investigational agents

- At least 14 days since prior radiotherapy

- No concurrent rapamycin (sirolimus)

- No concurrent enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or
phenobarbital), CYP3A4 inducers (e.g., rifampin or St. John's wort), or CYP3A4
inhibiting agents or substrates (e.g., ketoconazole, diltiazem, or verapamil)

- No concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or any
other type of therapy for treatment of this cancer while on this protocol

- No live vaccines

- Luteinizing-hormone releasing-hormone agonists allowed

- Concurrent prophylactic warfarin (≤ 1 mg/day) allowed

- Concurrent bisphosphonate or erythropoietin or its analogue allowed, if deemed
appropriate by the treating physician